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Abstract
Ullrich congenital muscular dystrophy (UCMD), caused by collagen VI deficiency, is a common congenital muscular
dystrophy. At present, the role of collagen VI in muscle and the mechanism of disease are not fully understood. To
address this we have applied microarrays to analyse the transcriptome of UCMD muscle and compare it to healthy
muscle and other muscular dystrophies. We identified 389 genes which are differentially regulated in UCMD relative
to controls. In addition, there were 718 genes differentially expressed between UCMD and dystrophin deficient
muscle. In contrast, only 29 genes were altered relative to other congenital muscular dystrophies. Changes in gene
expression were confirmed by real-time PCR. The set of regulated genes was analysed by Gene Ontology, KEGG
pathways and Ingenuity Pathway analysis to reveal the molecular functions and gene networks associated with
collagen VI defects. The most significantly regulated pathways were those involved in muscle regeneration,
extracellular matrix remodelling and inflammation. We characterised the immune response in UCMD biopsies as
being mainly mediated via M2 macrophages and the complement pathway indicating that anti-inflammatory treatment
may be beneficial to UCMD as for other dystrophies. We studied the immunolocalisation of ECM components and
found that biglycan, a collagen VI interacting proteoglycan, was reduced in the basal lamina of UCMD patients. We
propose that biglycan reduction is secondary to collagen VI loss and that it may be contributing towards UCMD
pathophysiology. Consequently, strategies aimed at over-expressing biglycan and restore the link between the
muscle cell surface and the extracellular matrix should be considered.
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Introduction
Ullrich Congenital Muscular Dystrophy (UCMD, OMIM
#254090), caused by collagen VI deficiency, is one of the most
common inherited myopathies [1]. It is characterized by
hypotonia, delayed motor milestones, proximal muscle
weakness, distal joint hyperlaxity and proximal joint
contractures within the first year of life. Patients at the severe
end of the of UCMD spectrum never achieve ambulation
whereas most patients walk independently but loose
ambulation around the early teenage years. Feeding difficulties
in childhood are also a relatively common feature, as
respiratory insufficiency which is almost invariable by the late
teens. Furthermore, a characteristic skin phenotype has been
described in collagen VI-related disorders [2,3][4].
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UCMD is caused by recessive or dominant mutations in any
of the three collagen 6 genes (COL6A1, COL6A2 and
COL6A3) which result in an absence or partial deficiency of
collagen VI around the muscle fibre. Collagen VI is secreted by
endomysial fibroblasts [5] and consists of three α chains,
namely α 1(VI), α 2(VI) and α 3(VI). They form heterotrimeric
monomers that align to form antiparallel dimers which align
laterally to form tetramers. These tetramers are secreted from
the fibroblast and associate in an end-to-end fashion to give
rise to the final microfilament network [2]. Collagen VI
microfibrils interact with various components of the muscle
basal lamina and extracellular matrix and may also interact
directly with the muscle cell via yet unknown surface receptors.
The function of collagen VI in skeletal muscle is still not fully
understood. Its position in close proximity to the basal lamina,
suggests that it acts by linking the basal lamina to the
extracellular matrix [6]. Previous works in cell cultures has
shown that collagen VI-deficient cells exhibit decreased
adherence to their surroundings [7,8]. Collagen VI deficiency
has also been associated with alterations of the mitochondrial
membrane permeability, which lead to increased cell death by
apoptosis, and with impaired autophagy supporting non-
structural roles in muscle as in other cell types [9-11]. Recent
work has linked defects in autophagic removal of mitochondria
(mitophagy) to muscular dystrophy associated with collagen VI
deficiency [12]. Defective mitophagy permits the accumulation
of damaged mitochondria that leads to mitochondrial swelling,
collapse of the mitochondrial membrane potential, and release
of pro-apoptotic factors, which have been implicated not only in
cell death but also in muscle fibre atrophy and injury [13,14].
At present, there are no available treatments for UCMD
although several strategies are being developed. Currently,
there is an open pilot trial with cyclosporine A, an
immunosuppressive agent, that seems to correct mitochondrial
dysfunction observed in muscles from UCMD patients
ameliorating the symptoms [15,16]. Another study is based on
the use of anti-apoptotic drugs in collagen VI and laminin-α2
deficiency [17]. However, there are concerns over the use of
anti-apoptotic and pro-autophagy treatments because of their
pleiotropic and potentially harmful effects. Therefore, identifying
more upstream modifiers may provide therapeutic targets
which are more specific and with less unwanted
consequences.
Previous studies have used microarray technology to identify
and describe molecular pathways implicated in other muscular
pathologies such as Duchenne Muscular Dystrophy (DMD)
[18-20][21-23], Limb-Girdle Muscular Dystrophy 2A (LGMD2A)
[24,25], Emery-Dreifuss muscular dystrophy (EDMD) [26],
facioscapulohumeral muscular dystrophy (FSHD) [27], X-linked
myotubular myopathy (XLMTM) [28] and inflammatory
myopathies [29] amongst others.
Previously, we have described that collagen VI deficiency
leads to concomitant and significant muscle cell atrophy and
regeneration [30] although the precise mechanism remained to
be elucidated. We sought to gain insight into genes and
pathways involved in this disease and increase our
understanding of the pathogenesis of this condition by using for
first time, gene expression arrays and comparing gene
expression patterns between UCMD, control and other
muscular dystrophies. Using this approach we have identified
significant changes in the transcriptome of UCMD relative to
normal and dystrophin deficient muscle. We describe
significant muscle regeneration, ECM remodelling and an
inflammatory component which is mediated by M2
macrophages and the complement system. Furthermore, we
have identified biglycan as a potential molecular target for
future therapeutic development and clinical research.
Material and Methods
Ethics Statement
This work has been approved by the Ethical Committee of
“Fundació Sant Joan de Déu”. Written informed consent for
research was obtained from all patients and healthy controls
(or their parents/guardians) according to the Hospital Sant
Joan de Déu forms and regulations.
Study Population
Open muscle biopsies from left quadriceps were performed,
oriented and frozen according to standard procedures [31].
Muscle tissue samples for microarray analysis were recruited
from 16 individuals: 6 UCMD patients, 3 DMD patients, 3 CMD
patients and 4 non pathological children. Lower limb muscle
samples were obtained from children non-affected by a
neuromuscular disease (control muscle group) who underwent
orthopaedic surgery at the Hospital Sant Joan de Déu.
Additional samples of UCMD patients were supplied by MRC
CNMD Bio Bank (London, UK), corresponding to patients P6
and P7, and by Hospital Virgen del Rocío (Sevilla, Spain),
patient P8. P9 was not included in the microarray analysis but
was studied by immunfluorescence. Detailed information on all
patients and controls is given in Table S1.
RNA isolation and First-strand cDNA Synthesis
Muscle biopsies were homogenized with TissueRuptor
(Qiagen, Hilden, Germany). Total RNA was extracted from
biopsies (30 mg) with RNeasy Fibrous Tissue mini kit following
the manufacturer’s instructions. Quantity and quality of RNA
obtained was determined with Nanodrop 8000
Spectrophotometer (Thermo Scientific, Schwerte, Germany)
and its integrity with Agilent 2100 Bioanalyzer (Agilent
technologies, Waldbronn, Germany). In all samples RNA
integrity numbers (RIN) were >7 and 260/280 ratios near 2.0.
0.15 mg of RNA was retro-transcribed with SuperScritp III
First-Strand Synthesis Super-Mix for qRT-PCR (Invitrogen™,
Carlsbad, CA, USA) to obtain cDNA and then was amplified
with Taqman PreAmp Master Mix (Applied Biosystems, Foster
City, CA, USA) following manufacturer’s instructions.
Microarray Analysis
RNA from muscle biopsies was amplified by MEGAScript T7
(Invitrogen™, Carlsbad, CA, USA) and retrotranscribed to
cDNA and labelled with the IVT kit. A total of 15 μg of labelled
cRNA was fragmented and hybridised to oligonucleotide
Agilent GE 1-color Human 8x60 K arrays (Agilent
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PLOS ONE | www.plosone.org 2 October 2013 | Volume 8 | Issue 10 | e77430
Technologies, Inc., Santa Clara, CA, USA). The current format
of these arrays interrogates 27,958 annotated genes in the
human genome and 7,419 lincRNAs (long intergenic noncoding
RNAs). Washes and scanning of the arrays were performed
according to manufacturer instructions. Expression values of
the 16 cy3-labeled samples were obtained using the
Bioconductor limma package [32], with background correction
("normexp") and "quantiles" normalization between arrays.
Statistical differential gene expression analysis between
groups was performed by the non-parametric approach Rank
Prod [33], which detects genes that are consistently highly
ranked in a number of replicate experiments, a method that has
shown robustness to outliers, being suitable for studies with
few biological samples. Those oligonucleotides that present
changes between groups with FDR (False Discovery Rate)
lower than 0.05 were considered significant. The web tool
DAVID [34], was used for the calculation of the functional over-
representation statistics of the different lists of significant genes
obtained with Rank Prod analysis. Gene Ontology Biological
Process (The Gene Ontology Consortium,
www.geneontology.org) and KEGG pathways (Kyoto
Encyclopedia of Genes and Genomes, www.genome.jp/kegg)
databases were considered. Also, interaction networks have
been constructed using the Ingenuity Pathways Analysis tool
(IPA) (http://www.ingenuity.com), based on extensive records
maintained in the Ingenuity Pathways Knowledge Base (IPKB)
database.
Real-Time Quantitative RT-PCR
High-throughput real-time qPCR was performed according to
the manufacturer's protocol on the BioMark 48.48 Dynamic
Array (Fluidigm®, South San Francisco, CA, USA) with Taqman
Gene Expression Assays. List of Taqman Gene Expression
Assays used is provided in Table S2. qRT-PCR was run in
triplicates in all samples and TATA box binding protein (TBP)
and hypoxanthine phosphoribosyltransferase 1 (HPRT1) were
used as endogenous control genes to normalize transcription
levels amongst patients. Results were analysed with qBaseplus
software (Biogazelle, Zwijnaarde, Belgium). Fold-changes of
the genes of interest were calculated as mean values of 2-∆∆CT
or 1/2-∆∆CT relative to healthy controls. A fold-change above or
below 1.5 was considered significant.
Antibodies and Immunostaining
Cryosections (7 μm thick) were labelled without prior fixation
using primary antibodies diluted in PBS 0.1 % Tween-20.
Detailed information on primary antibodies used is provided in
Table S3. Immunofluorescence was visualised with species-
specific secondary antibodies directly linked to Alexa-
fluorophores (Molecular Probes, Eugene, OR, USA). Nuclei
were visualised using DAPI (Molecular Probes, Eugene, OR,
USA) diluted in PBS 0.1% Tween-20. Immunohistochemistry
was performed using Novo-Link peroxidase detection kit
according to manufacturer’s instructions (Novo-Link peroxidase
detection kit, Leica Microsystems, Wetzlar, Germany). Working
dilutions were optimised for each antibody and non-specific
labelling was assessed using sections incubated without
primary antibodies.
Immunofluorescence was visualised under a conventional
epifluorescence microscope (Leica DM5000B) or under a
confocal microscope (TCS-SP2 Leica confocal microscope).
Images were acquired with Leica Imaging Suite (LAS) and
were quantified with ImageJ software.
Quantitation of fibrosis
The extent of connective tissue was measured on collagen
VI immunostained sections as previously described [35] using
the NIH Image software version 1.44 (http://rsb.info.nih.gov/nih-
image/). At least six fields from each patient were analysed.
The area positive for collagen VI was calculated as a
percentage of the entire image. The mean and standard
deviation (SD) was then obtained for control and each disease
group from the total of all analysed fields.
Statistical analysis
Average values are expressed as mean ± standard error
(MEAN ± SE). Significance was tested by Student unpaired t-
test and P-value <0.05 was considered as significant (NS, non-
significant, *P < 0.05, **P < 0.01 and ***P < 0.001).
Results & Discussion
Overview
We used Agilent GE 1-color Human 8X60K microarrays to
identify differences in gene expression between UCMD
muscles, control muscles and other muscular dystrophies.
This approach has been used before to describe the
molecular mechanisms involved in other muscle diseases such
as DMD [18-21][36], LGMD2A [24,25], FSHD [27], Emery-
Dreifuss muscular dystrophy (EDMD) [26], X-linked myotubular
myopathy [28] and inflammatory myopathies [29].
UCMD and other myopathy patients and controls were
adequately differentiated by non-supervised hierarchical
clustering analysis, showing considerable heterogeneity,
whereas no mutation, age or genre effects were observed in
the whole dataset. Then, we proceeded to perform the
supervised statistical analysis with a method –RankProd- which
has largely shown important effectiveness detecting genes that
are consistently highly ranked in a number of replicate
experiments, even when a small number of heterogeneous
replicates are available. We identified 389 individual genes
whose expression levels were significantly changed in UCMD
muscles with respect to control muscles using the selection
criteria of False Discovery Rate (FDR) < 0.05. A full gene list is
provided in Table S4. Of these, a majority 319 genes were up-
regulated and only 70 genes were down-regulated (Table 1).
The top 10 significant differentially expressed genes are listed
in Table 2. The list of up-regulated genes included some
involved in regeneration and differentiation (MYH8, myosin
heavy chain perinatal; S100B, S100 calcium binding protein
beta), genes involved in the formation of lipid droplets and
ketogenesis (CIDEA and CIDEC, cell death-inducing DFFA-like
effector A and C, PLIN1, perilipin), genes encoding adipokines
(RBP4, retinol binding protein 4; ADIPOQ, adiponectin) and
various galectins (LGALS7, galectin-7; LGALS12, galectin-12).
Gene Expression Profiling in UCMD
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In the list of down-regulated genes were included those
involved in protein synthesis (IGFN1, immunoglobulin-like and
fibronectin type III domain containing 1), cell cycle and cell
survival (GADD45G, growth arrest and DNA-damage-inducible,
gamma; AKR1B10, aldo-ketoreductase family 1 member B10),
transducers of intracellular signals (ARRDC2, arrestin domain
containing 2), secreted proteases (ADAMTS8, ADAM
metallopeptidase with thrombospondin type 1 motif 8), TNF-
receptors (RELT, tumor necrosis factor receptor), sarcomeric
components of the Z-disk (ACTN3, actinin alpha 3) and others
genes that codify proteins of unknown function (KLHL34, kelch-
like 34; ZMYND17, zinc finger MYND domain containing 17).
Data has been deposited at the National Centre for
Biotechnology Information Gene Expression Omnibus (GEO)
database as GEO Series accession number GSE43698. 
In order to understand the biological significance of the
observed changes we analyzed the differentially expressed
UCMD muscle genes using DAVID Bioinformatics Resources
(v6.7) web tool [34,37] that provides information of gene
ontology (GO) classification and KEGG pathways, identifying
significantly enriched themes.
Only GO BP (Gene Ontology Biological Process) categories
with % FDR<20 were considered relevant. We found 146
significant GO BP categories of up-regulated genes (listed in
Table S5) which were grouped in more general functional
categories as shown in Figure 1. Among the most enriched
biological processes of up-regulated genes were those related
to the immune response, extracellular matrix and adhesion,
regeneration, cell signalling and lipid and glucose metabolism;
whereas only 6 significant GO categories of down-regulated
genes were described including genes involved in catabolic
processes (Table 3).
Concordant results were obtained when using KEGG
database, although only up-regulated genes showed a
significant association with KEGG pathways. A full pathway list
is given in Table S6.
Increased susceptibility to apoptosis, impaired activation of
autophagy and accumulation of dysfunctional mitochondria and
sarcoplasmic reticulum have been implicated in the
pathogenesis of UCMD in both mice and human [9,12].
Therefore we looked for enrichment of these and related
molecular functions amongst the set of regulated genes in
UCMD versus control muscle using GO and KEGG. We did not
Table 1. Number of regulated genes in UCMD vs control
muscle, DMD and CMD.
 UCMD vs Control UCMD vs DMD UCMD vs CMD
 Down Up Down Up Down Up
FDR < 0.05 70 (118) 319 (658) 421 (552) 297 (643) 29 (38) -
FDR < 0.01 8 (13) 116 (241) 52 (62) 57 (111) 13 (15) -
FDR < 0.05 & IPA
SKM
53 257 211 258 21 -
Numbers in brackets represent numbers of oligonucleotides regulated in the
microarray. FDR, False Discovery Rate. IPA SKM, filtered for expression in
skeletal muscle by Ingenuity Pathway Database.
doi: 10.1371/journal.pone.0077430.t001
find any significantly over or under represented GO_BP or
canonical pathway associated with apoptosis, mitochondria or
autophagy suggesting that these processes are not regulated
at the gene transcription level. In contrast we found 2 GO_BP
categories related to calcium homeostasis.
Table 2. Top ten changes in UCMD vs Control.
Gene symbolGene description FC FDR
IGFN1
Immunoglobulin-like and fibronectin type III domain
containing 1
-8.8 0
GADD45G Growth arrest and DNA-damage-inducible, gamma -4.6 0.0011
KLHL34 kelch-like 34 -4.1 0.0011
AKR1B10
Aldo-keto reductase family 1, member B10 (aldose
reductase)
-3.7 0.002
ARRDC2 Arrestin domain containing 2 -4.1 0.0027
ZMYND17




ADAM metallopeptidase with thrombospondin type
1 motif, 8
-4.1 0.0071
RELT Tumor necrosis factor receptor -3.1 0.01
ACTN3 Actinin alpha 3 -3.0 0.01
HPDL 4-hydroxyphenylpyruvate dioxygenase-like -3.0 0.01
MYH8 Myosin, heavy chain 8, skeletal muscle, perinatal 57.7 0
RBP4 Retinol binding protein 4 19.6 0
CIDEC Cell death-inducing DFFA-like effector c 11.6 0
LGALS7 Galectin 7 10.9 0
ADIPOQ Adiponectin 9.6 0
PLIN1 Perilipin 1 9.4 0
S100B S100 calcim binding protein B 8.0 0
HMGCS2 3-hydroxy-3-m3thylglutaryl-CoA synthase 2 7.5 0
HLA-DQA1
Major histocompatibility complex, class II, DQ
alpha 1
5.3 3.33E-04
LEP Leptin 5.1 3.33E-04
FC, Fold-change; FDR, False Discovery Rate.
doi: 10.1371/journal.pone.0077430.t002
Figure 1.  GO BP categories in UCMD vs control
muscle.  Pie chart representing GO BP categories up-
regulated in UCMD vs control muscle.
doi: 10.1371/journal.pone.0077430.g001
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IPA analysis
In order to corroborate which are the most significant
biological functions revealed before by enrichment analysis and
to identify novel relationships among genes associated with
UCMD, all the significantly regulated genes were subjected to
IPA® analysis. This software revealed the signalling and
metabolic pathways and biological process that are most
significantly perturbed in UCMD (Table 4). Besides, 10 well
ranked gene networks were derived by this tool (Listed in Table
S7). The best ranked ones were those related to connective
tissue disorder, lipid metabolism and inflammatory disease. IPA
also identified 34 activated and 8 inhibited upstream
transcriptional regulators in the list of significant genes
suggesting that collagen VI plays a role in the regulation of
gene transcription. Three of these genes were also significantly
over-expressed in the UCMD group, supporting the importance
of their function: PPARG, CEBPA and EGR1. Previous works
showed some evidences that soluble collagen VI plays a role in
proliferation by up-regulating cyclins A, B, and D1 [38] and
survival through down-regulation of the proapoptotic Bax
protein [39] of fibroblasts and in the regulation and
differentiation of adipocytes [40]. Besides, other components of
the ECM such as tenascin X have been described to regulate
gene expression [41,42]. We represented the merging of three
interesting mechanistic networks (2, 6 and 8: connective tissue
disorder, lipid metabolism and inflammatory response,
respectively) to describe plausible connections among
upstream regulators and the observed gene expression
changes and to point out the tight relationship between them
(Figure 2). The outstanding hub genes connecting these 3
networks were adiponectin (ADIPOQ, +9.60), adipsin (CFD,
+4.60) and an aldo-keto-reductase (AKR1B10, -3.7).
We focused on a selection of representative aspects of
UCMD pathophysiology (muscle regeneration, extracellular
matrix remodelling, immune response and protein synthesis)
for further studies.
Muscle regeneration & maturation
In muscle from UCMD patients we observed the post-natal
expression of developmental isoforms of sarcomeric proteins
such as embryonic myosin (MYH3, +4.12), perinatal myosin
(MYH8, +57.65) and cardiac troponin T2 (TNNT2, +6.87). This
would be in line with the persistent expression of perinatal
myosin in a significant percentage of fibres in UCMD muscle
(up to 30%) as we and others have demonstrated by
immunohistochemistry [43][30].We also observed an over-
expression of genes encoding components of the cytoskeleton
such as different isoforms of myosin light chains (MYL5, +3.71;
MYL9, +2.33) and other cytoskeletal elements (ACTG, +3.11;
TUBB6, +2.33) supporting chronic remodelling of the
cytoskeleton [18]. However, PAX7 (which is expressed by
satellite cells) and early myogenic markers (MYOD, MYOG,
CD56 and CDH15) were not amongst the regulated genes in
UCMD versus normal muscle.
We sought to identify the regenerative mechanisms active in
UCMD skeletal muscle based on the gene expression data.
Insulin pathway is one of the most important mechanisms
Table 4. IPA functional analysis performed with UCMD vs
control significant genes.
Category Top functions p-value # genes
Diseases and disorders   
1 Cancer 3.48E-34 - 1.36E-04 200
2 Reproductive System Disease 6.38E-24 - 1.36E-04 127
3 Connective Tissue Disorders 3.68E-20 - 1.93E-05 110
4 Skeletal and Muscle Disorders 3.68E-20 - 1.15E-04 130
5 Inflammatory Disease 1.04E-19 - 6.83-05 110
Molecular and Cellular Functions   
1 Cellular Movement 1.01E-16 - 1.44E-04 101
2 Cell-to-Cell Signaling and Interaction 4.46E-14 - 1.26E-04 86
3 Lipid Metabolism 7.97E-13 - 8.07E-05 72
4 Small Molecule Biochemistry 7.97E-13 - 1.44E-04 98
5 Cell Death and Survival 1.66E-12 - 1.15E-04 125
Physiological System Development and
Function
  




1.62E-15 - 1.44E-04 109
3
Connective Tissue Development and
Function
3.74E-12 - 1.44E-04 87
4 Tissue Morphology 3.74E-12 - 1.15E-04 114
5 Organismal Development 1.92E-09 - 9.96E-05 107
doi: 10.1371/journal.pone.0077430.t004
Table 3. GO categories of significant down-regulated genes.
GO term p-value Genes FDR
Posttranscriptional regulation of gene expression 0.00338724 NANOS1, MKNK2, PEX6, GDNF, SAMD4A 4.800500143
Modification-dependent protein catabolic process 0.00638154 NEDD4, USP38, FBXO32, ASB2, TRIM63, CISH, USP31 8.864571736
Modification-dependent macromolecule catabolic process 0.00638154 NEDD4, USP38, FBXO32, ASB2, TRIM63, CISH, USP31 8.864571736
Proteolysis involved in cellular protein catabolic process 0.00787657 NEDD4, USP38, FBXO32, ASB2, TRIM63, CISH, USP31 10.83270743
Cellular protein catabolic process 0.00806415 NEDD4, USP38, FBXO32, ASB2, TRIM63, CISH, USP31 11.07683549
Protein catabolic process 0.00932847 NEDD4, USP38, FBXO32, ASB2, TRIM63, CISH, USP31 12.70613535
FDR, False Discovery Rate.
doi: 10.1371/journal.pone.0077430.t003
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Figure 2.  Merging of three well scored IPA networks of regulated genes in UCMD patients.  Gene networks involved in
Connective Tissue Disorders, Dermatological Diseases and Conditions, Gastrointestinal Disease (network 2, Table S4); Lipid
Metabolism, Molecular Transport, Small Molecule Biochemistry (network 6); and Inflammatory Response, Cellular Movement,
Haematological System Development and Function (network 8). The intensity of the node color indicates de degree of up-(red) or
down- (green) regulation in UCMD compared to control. Genes in uncoloured notes were not identified as differentially expressed in
our experiment and were integrated into the computationally generated networks on the basis of the evidence stored in the IPA
knowledge database indicating a relevance to this network. Nodes are displayed using various shapes that represent the functional
class of the gene product.
doi: 10.1371/journal.pone.0077430.g002
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regulating regeneration and size of the muscle fibre [44].
Insulin –like growth factor I (IGF-I), whose expression is known
to be up-regulated in regenerating muscle in vivo, positively
regulates the proliferation and differentiation of satellite cells/
myoblasts in vitro via the Akt/PKB pathway [45] and calcineurin
[46]. In line with this, in the present study we observed that
IGF-I and its isoform IGF-II, were up-regulated in UCMD
muscle (+2.50 and +2.60, respectively).
Additionally, follistatin (FST) was up-regulated in UCMD
muscle (+4.10). Over-expression of this gene may promote
muscle regeneration via blockage of myostatin signalling [47].
Furthermore, one of the most up-regulated genes was
S100B (+8.00), a calcium-binding protein of the EF-hand type.
It has been previously described that this protein stimulates
myoblasts proliferation but inhibits myogenic differentiation and
myotube formation [48-51], lending support to the suggestion
that incomplete maturation may play a part in the pathogenesis
of UCMD [43] [30].
Extracellular Matrix remodelling
UCMD patients showed increased expression of a large
number of genes encoding Extracellular Matrix (ECM)
components. In order to find out if these changes were
associated with an increase in fibrosis we quantified
endomysial and perimysial fibrotic area in control, DMD and
UCMD muscle by calculating percentage of the area occupied
by Collagen VI with ImageJ software as reported previously
[35]. None of the patients included in this study showed
complete absence of collagen VI. They all showed a partial
reduction at the basal lamina but normal expression in the
endomysium which allowed us to quantify fibrotic area. We
determined that in UCMD there was an increase of connective
tissue which was comparable to the extent of fibrosis found in
early phases of DMD (9.82 ± 2.07; 25.83 ± 1.28 and 22.61 ±
1.85 % of fibrosis per area; in control, DMD and UCMD,
respectively) (p = 0.087) (Figure S1).
Corresponding with the level of fibrosis in UCMD, the
principal ECM forming collagens (types I and III) were up-
regulated (+5.48 and +3.85, respectively). Type V collagen,
another fibril-collagen that associates with types I and III, was
also up-regulated (+3.26) as well as collagens with interrupted
triple helices (FACITs), types XII (+2.70), XIV (+3.34), XIX
(+4.13) and XXI (+3.16) whose function is to link fibrillar
collagen to other ECM components and some of them, XII and
XIV, which are expressed during skeletal muscle development.
Short chain collagen that forms hexagonal networks, type VIII,
was also up-regulated (+4.14). Recently, three novel collagen
VI alpha chains (α4, α5 and α6) have been described although
only COL6A6 is expressed in human skeletal muscle [52]. Most
of our UCMD patients presented COL6A1 mutations and, as
previously have been reported in skin, COL6A6 was altered
(+2.37) [53]. Changes in COL6A6 have also been reported in
Duchenne muscular dystrophy suggesting that it is implicated
in muscle fibrosis [54].
Biglycan (BGN) and lumican (LUM) are members of the
small leucine-rich proteoglycan (SLRP) family of ECM
proteoglycans. Both genes were over-expressed in UCMD
skeletal muscle (+2.26, +3.17). Lumican has been previously
identified to interact with fibrillar collagens and can interfere
with collagen fibrillogenesis. It has a stimulatory effect on the
epithelial-mesenchymal transition state to fibrosis induced by
transforming growth factor β (TGF-β). Biglycan, in addition to
binding to fibrillar collagens I and III, interacts directly with
collagen VI [55,56] [57] and is known to form a connection
between the extracellular collagenous matrix and the
dystrophin-associated protein complex (DAPC) via its binding
to α-dystroglycan [58], α-sarcoglycan and γ-sarcoglycan [59]. It
is also considered a signalling molecule because it interacts
with growth factors and their receptors and recently it has been
established as a part of the innate immune system [60].
It has been described previously that in DMD and congenital
muscular dystrophy 1A (MDC1A), biglycan expression at
mRNA and protein level is up-regulated reflecting the extent of
the fibrosis present in these dystrophies [35] [61]. However,
changes in biglycan immunolocalisation have not been
previously reported in UCMD. To investigate this we performed
immunofluorescence against biglycan in muscle sections. In
normal controls (n=6) biglycan was located predominantly in
the perimysium and on the surface of the muscle fibres. In
DMD muscle (n=3), biglycan was expressed similarly to
controls except that the endomysial and perimysial
compartments were more extensive, suggesting that presence
of biglycan increases in relation to increased fibrosis in
dystrophic muscle [58]. In UCMD muscles, biglycan was
increased in the connective tissue, confirming microarray data.
However, it was partially reduced at the muscle fibre basal
lamina, relative to perlecan, in all 8 UCMD muscle samples
analysed (7 genetically confirmed and one awaiting
confirmation) compared to normal muscle. This specific
reduction was confirmed using confocal microscopy.
Representative images are shown in Figures 3 and 4. Given
that collagen VI and biglycan are known to interact directly we
hypothesise that the partial reduction in biglycan is secondary
to collagen VI deficiency and may be contributing to the muscle
dysfunction in UCMD .
Previous studies have shown that biglycan over-expression
regulates the sarcolemmal localization of α-sarcoglycan and γ-
sarcoglycan [59], dystrobrevin [58], syntrophin, nNos [62] and
utrophin [63] improving muscle integrity. Consequently, over-
expression of biglycan is considered as a novel therapeutic
target for DMD [63,64]. Similarly, over-expression of biglycan
may restore localization of collagen VI at the basal lamina
(where collagen VI reduction takes place in most UCMD
patients) and thus strengthen binding of the muscle cell to the
ECM improving muscle integrity and function in collagen VI
deficiency.
Tenascin-X, an extracellular matrix glycoprotein which is
produced by fibroblasts, was also up-regulated (+2.70). It is
known that tenascin X interacts with types I, III and V collagen
molecules and also binds to the fibril associated types XII and
XIV collagens, therefore playing a crucial role in the
organisation of ECM [65][66]. Moreover, tenascin X regulates
the expression of type VI collagen at the transcriptional level
promoting its synthesis [41]. Thus, up-regulation of tenascin X
in UCMD muscles may be a compensatory mechanism to
increase collagen VI production. In line with this we observed
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an increase of COL6A1 and COL6A6 mRNA expression (fold-
change of 2.6 and 2.4, respectively) although COL6A2 and
COL6A3 were not significantly changed in UCMD versus
control muscle.
Other components of the ECM such as Laminin alpha 4
(+3.38), Nidogen 2 (+2.73) and Fibulin 1 and 5 (+2.26) were
also induced.
Immune response
Our data indicate that collagen VI deficiency leads to
activation of an immune response. We found increased
expression of Class I and Class II Major Histocompatibility
Complex (MHC) genes including beta-2-microglobulin (B2M,
+2.3), HLA-B (+2.3) and HLA-F (+2.4). We investigated this
further by immunohistochemistry for HLA-I antigen in UCMD
muscle. We observed widespread HLA expression on the
membrane of most muscle fibres and in the cytoplasm of some
regenerating fibres, identified by perinatal myosin staining. In
addition immunohistochemistry revealed inflammatory cell
infiltrates in UCMD muscles. In contrast, in control muscle only
capillaries and endothelial cells expressed HLA (Figure 5).
Next, we examined inflammatory features in the skeletal
muscle of UCMD patients. In control muscle, resident
macrophages could be found in both the epimysium and the
perimysium, but rarely found in the endomysium. However, in
UCMD muscle we observed abundant endomysial infiltration
and rarely perivascular inflammation by immune cells with
morphological features resembling macrophages.
To investigate the origin of inflammatory cells we performed
immunohistochemistry against different cell markers including
CD3, CD20 and CD68 that identify T cells, B cells and
macrophages, respectively. We demonstrated that in UCMD
the immune cells were macrophages, because they were
positive for the macrophage marker CD68 and nor for the other
cell markers. We corroborated this finding with acid
phosphatase staining (data not shown). Various macrophage
Figure 3.  Biglycan immunolocalisation in UCMD muscle biopsies.  Biglican (red) and perlecan (green) conventional
immunofluorescence in muscle sections of controls (A-C), UCMD patient 9 (D-F) and patient 2 (G-I) showing a variable degree of
biglican reduction. Scale bar: 50 µm.
doi: 10.1371/journal.pone.0077430.g003
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phenotypes could be present in muscle. ‘Classically activated’
macrophages (M1) produce both pro-inflammatory cytokines
and nitric oxide, promoting muscle damage whereas
‘alternative activated’ macrophages (M2) are involved in
muscle regeneration because they attenuate the inflammatory
response and promote tissue repair. CD206 is a mannose
receptor that is expressed by all M2 macrophages. In UCMD
approximately 74% of CD68+ macrophages were also positive
for the M2 type macrophage marker CD206 (Figure 4).
Therefore, in UCMD muscle there is an important inflammatory
component which consists mainly of M2 macrophages. In line
Figure 4.  Secondary reduction of biglycan at the basal lamina of UCMD patients.  The integrity of the basal lamina and the
reduction of biglycan was further studied using confocal microscopy. An example for UCMD patient 6 at two different magnifications
is shown. Arrows point to representative areas where biglycan (A, D, G) appears reduced relative to perlecan (B, E, H). Scale bar:
50 µm.
doi: 10.1371/journal.pone.0077430.g004
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with this CCL-18, which is an anti-inflammatory cytokine
secreted by M2 macrophages, was also up-regulated (+3.19).
It is not clear what triggers the inflammatory response in
UCMD but over-expression of MHC-class I components
suggest an autoimmune component which may be directed
towards the abnormal collagen VI which is produced by these
patients. Besides, the expression of components of the MHC-
class II was also up-regulated in the microarrays, probably as a
consequence of the presence of inflammatory cells in muscle.
We determined that these inflammatory cells corresponded
mainly to macrophages (CD68 positive) M2-type (CD260
positive), that promote tissue repair. Macrophage infiltration is
thought to contribute to muscle wasting in DMD and their
depletion or inhibition as been shown to significantly decrease
dystrophic muscle pathology [67]. Glucocorticoids, more
precisely prednisone and deflazacort, are the main drug
treatment to DMD patients with established clinical efficacy in
increasing muscle strength and slowing the progression of the
illness [68]. It has been postulated that the benefit of
corticosteroid treatment might be attributed to the anti-
inflammatory as well as the immunosuppressive effect [69]. In
view of our results, the potential beneficial effect of
corticosteroid treatment in UCMD patients should be
considered.
Our results indicate that classical as well as alternative
complement pathways are activated and possibly contribute to
muscle damage in UCMD. We identified the complement
factors C1R (+2.30), C1S (+2.31), C3 (+6.30), C4B (+2.48), C7
(+2.49) and CFD (+4.58), as differentially expressed. In order
to validate these results we measured the RNA levels of C3, a
central component of the complement system, confirming its
up-regulation in UCMD muscles. Complement system
activation is not an exclusive feature of UCMD because it has
been described in other muscular dystrophies [70] such as
DMD [71], dysferlinopathy (LGMD2B) [72] and merosin
deficiency (MDC1A) [73][74] where it is thought to contribute to
membrane damage and macrophage recruitment amplifying in
turn the immune response and muscle damage. In a mouse
model of LGMD2B, other authors confirmed the active role of
complement activation in the progression of muscular
dystrophy and the attenuation of muscle pathology following
the disruption of C3 providing a new therapeutic target for
muscular dystrophies [75].
Protein catabolism
70 genes were found significantly down-regulated in UCMD
versus control muscle (Table 1). DAVID analysis identified 6
significant GO BP terms (with % FDR<20) to be associated to
these down-regulated genes. All of them were related to
protein degradation by the ubiquitin-proteasome system. These
GO BP terms contained 7 unique genes: USP31 (-2.60),
USP38 (-2.40), ASB2 (-2.00), NEDD4 (-2.20), FBXO32 (-3.40)
Figure 5.  Characterization of inflammation found in UCMD muscle.  HLA immunostaining in healthy muscle sections located in
the endothelial cells of capillaries (A). Sarcolemmal and cytoplasmatic HLA staining on UCMD muscle sections including strong
staining of mononucleated cells (B). Immunohistochemistry for CD68 demonstrate macrophage infiltration (C).
Immunohistochemistry for CD206 identified M2-type macrophages (D). Arrows point to mononucleated cells CD68+ and CD206+
whereas arrowheads point to only CD68+ cells. Scale bar: 50 µm.
doi: 10.1371/journal.pone.0077430.g005
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and TRIM63 (-3.20). We had previously described down-
regulation of two of these genes in UCMD muscle by means of
qRT-PCR: FBXO32 encoding the E3-ubiquitin ligase, atrogin-1
(MAFbx) and TRIM63 encoding Muscle RING Finger-1
(MuRF1) [30].
In contrast, the autophagy-lysosomal system, another
mechanism for protein degradation, was not regulated. Grumati
et al. [12] have previously described defective autophagy in a
collagen VI-knockout (Col6a1-/-) mice and human. Muscles
from Col6a1-/- mice showed reduced LC3-I to LC3-II conversion
and had reduced levels of beclin-1 and Bnip-3 at protein level
as well as in muscle biopsies derived from UCMD and BM
patients. However, in our data we did not observe any changes
in BECN1 (Beclin-1) and BNIP3 mRNA levels although a slight
non-significant reduction of LC3-II (MAP1LC3a) was observed.
Furthermore, non GO category or KEGG pathway related to
autophagy was significant.
Mitochondria and endoplasmic reticulum
Ultrastructural abnormalities in mitochondria and
endoplasmic reticulum (enlarged and swollen organelles),
mitochondrial dysfunction due to dysregulation of the
permeability transition pore (PTP) and calcium homeostasis
defects have been described in collagen VI knocked-out mice
and UCMD muscles [9]. Previous works have described a
higher incidence of apoptosis in biopsies from UCMD patients
using TUNEL labelling [15,76]. In contrast, as we previously
reported, in our group of UCMD patients we did not find
evidence of muscle cell death by apoptosis (by active
caspase-3 and TUNEL immunostaining) [30].
In accordance with our previous results, no significant
functional categories related to apoptosis were identified in the
present study.
However, GO (Table S5) and IPA analysis identified two
canonical pathways related to calcium homeostasis as a
significantly altered (Calcium-induced T Lymphocyte Apoptosis
and Calcium Signaling with p-values 0.0018 and 0.0042,
respectively) in UCMD muscle relative to normal muscle. We
found down-regulation of SERCA1 (ATP2A1) (-1.9) suggesting
decreased Ca2+ uptake by the sarcoplasmic reticulum.
Comparison with other muscular dystrophies
In order to identify UCMD specific gene expression patterns
we also analysed other muscular pathologies including DMD,
as a paradigm of muscular dystrophy, and other forms of
congenital muscular dystrophies associated with either FKRP
or laminin-α2 deficiency (CMD group, see materials and
methods). We identified 718 (1195) genes (oligos) whose
expression was changed significantly in UCMD versus DMD,
297 (643) of them were up-regulated and 421 (552) genes
(oligos) were down-regulated (Table 1).
Significant genes in this comparison together with fold
changes are listed in Table S8. The down-regulated genes in
UCMD versus DMD included some involved in regulation of
transcription (HMBOX1 and SPEN), cellular DNA damage
response (RPA4), autophagy (VPS18), tumor suppression
(LRRC2), IGFN1, DDN and a macrophage marker (CD68).
The most up-regulated genes were HMGCS2, one of the
main enzymes for ketone-body synthesis, ANGPTL4, that
mediates PPAR delta effect on fatty acid uptake, RBP4, an
adipokine related to inflammation and insulin sensitivity and
some molecules of major histocompatibility complex class II
responsible of presenting peptides derived from extracellular
proteins.
Bioinformatics analysis with DAVID comparing identified 122
significant GO BP terms, 115 of them for up-regulated genes
and 7 for down-regulated ones (GO BP Categories were listed
in Table S9). Similarly, 15 significant KEGG pathways were
identified for up-regulated genes and 4 for down-regulated
ones, listed in Table S10.
These data indicated that markedly different pathways are
involved in the pathophysiology of both types of muscular
dystrophy.
Perhaps surprisingly only 29 (38) genes (oligos) were
differentially under-expressed in UCMD compared to CMD
(Table 1). Adequately, bioinformatics analysis with DAVID
comparing UCMD with other CMD did not obtain any significant
GO BP term nor KEGG pathway enriched theme (a full gene
list is provided in Table S11). CD86 was the most differentially
expressed gene (-8.80). In other forms of CMD regeneration
was more prominent than in UCMD as shown by the
expression levels of embryonic myosin (MYH3, -5.35) and
prominin 2 (also called CD133) a marker of muscle derived
stem cells (PROM2, -4.55). Markers of oxidative stress
(GSTT1) and autophagy (VPS18) were down-regulated in
UCMD versus other forms of CMD.
Thus, these data suggest that in contrast to DMD, UCMD
muscle shares several pathological mechanisms in common
with other forms of CMD, at least at the transcriptional level.
Validation of array results with real-time quantitative
PCR
The altered expression for 24 genes chosen from those
identified in the microarray was analyzed by real-time PCR
using the BioMark 48.48 Dynamic Arrays (Table 5). In total, we
analysed 4 control muscle samples (Control 1, 2, 3 and 5,
Table S1) and 7 UCMD muscle samples (UCMD 3, 4a, 4b, 5,
6, 7 and 8, Table S1) which include three additional samples
not present in the microarrays. One of the most up-regulated
genes in the microarray, RBP4, was one of these selected
genes. Other genes were selected to represent the most
regulated GO terms, i.e. regeneration (TNNT2), remodelling of
the extracellular matrix (COL14A1, COL19A1, COL21A1, DPT,
LUM, MGP and TNXB), inflammation and complement system
(CCL21, CXCL9 and C3), lipid metabolism and adipokines
(PPARG, HMGCS2, PLIN1, ADIPOQ and LEP) and other
representative down-regulated genes (IGFN1 and NEDD4).
Conclusions
This is the first report applying global gene expression
analysis to identify biological functions and pathways involved
in UCMD skeletal muscle pathophysiology. In addition to
identifying the set of genes differentially expressed in UCMD
versus normal muscle, we identified genes differentially
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expressed between UCMD and DMD and between UCMD and
other forms of CMD. The few gene expression changes
identified between the latter two groups indicate that the
pathways implicated in distinct forms of CMD pathologies may
be very similar. Therefore, the study of these genes and
pathways could be helpful to better understand the
mechanisms involved more generally in CMDs.
Furthermore, we have identified a secondary reduction in
biglycan in the basal lamina of collagen VI deficient muscle
fibres. We hypothesise that biglycan over-expression could
help restore the link between the basal lamina and the
extracellular matrix and improve muscle pathology in UCMD.
Additionally, we suggest that corticosteroid treatment and
attenuation of the complement component 3 may help slow the
progression of the disease although further research is
required to elucidate the role of the immune system in the
context UCMD.
Supporting Information
Table S1.  List of patients.
(DOCX)
Table 5. Comparison of fold-changes obtained by
microarray and by real-time PCR.
Gene Microarray Fluidigm
 FC q-value FC SE
IGFN1 -8.82 0 -18.83 ± 0.48
NEDD4 -2.22 0.3464286 -2.43 ± 0.08
TNXB +2.70 0.03189453 +1.10 ± 0.18
PPARG +2.76 0.01098361 +2.36 ± 0.17
COL21A1 +3.16 0.00699074 +3.36 ± 0.38
LUM +3.17 0.01145098 +1.73 ± 0.45
MGP +3.20 0.00757991 +1.87 ± 0.48
CCL21 +3.31 0.00371429 +2.28 ± 0.60
COL14A1 +3.34 0.02665944 +2.41 ± 0.84
DPT +3.37 0.0047449 +2.34 ± 0.21
CXCL9 +3.72 0.00275362 +4.24 ± 1.54
COL19A1 +4.13 0.00190909 +50.19 ± 1.28
FST +4.14 0.00155556 +5.64 ± 0.38
CEBPA +4.65 0.00111111 +6.19 ± 0.19
MGST1 +5.06 0.00046900 +5.32 ± 0.44
LEP +5.10 0.00033300 +27.52 ± 1.36
PTPRF +5.69 0.00045500 +6.46 ± 0.41
C3 +6.30 0.00045500 +5.28 ± 0.37
TNNT2 +6.87 0.00045500 +15.07 ± 0.64
HMGCS2 +7.50 0 +8.59 ± 1.72
PLIN1 +9.45 0 +13.89 ± 0.76
ADIPOQ +9.61 0 +23.35 ± 0.62
LGALS7 +10.89 0 +7.75 ± 0.32
RBP4 +19.56 0 +18.63 ± 0.64
FC: Fold-change; SE: standard error. Fold-changes were calculated as mean
values of 2- ∆∆CT or 1/2- ∆∆CT relative to healthy controls. A fold-change above or
below 1.5 was considered significant.
doi: 10.1371/journal.pone.0077430.t005
Table S2.  List of Gene Expression Taqman Assays.
(DOCX)
Table S3.  List of primary antibodies.
(DOCX)
Table S4.  List of gene changes FDR<0.05 UCMD vs
control.
(XLSX)
Table S5.  List of significant GO BP categories in UCMD vs
control muscle.
(XLSX)
Table S6.  List of significant KEGG pathways in UCMD vs
control muscle.
(XLSX)
Table S7.  List of significant gene networks (IPA) in UCMD
vs control.
(XLSX)
Table S8.  List of gene changes FDR<0.05 in UCMD vs
DMD.
(XLSX)
Table S9.  List of significant GO BP categories in UCMD vs
DMD.
(XLSX)
Table S10.  List of significant KEGG pathways in UCMD vs
DMD.
(XLSX)
Table S11.  List of gene changes FDR<0.05 in UCMD vs
CMD.
(XLSX)
Figure S1.  Quantification of fibrosis. Representative images
of muscle sections of healthy control (A), UCMD patient (B)
and DMD patient (C) immunolabelled against collagen type VI
used to perform quantification of fibrosis with ImageJ software.
Scale bar: 50 µm.
(TIF)
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